Company intelligence / Profile preview

mindcaps

Ownership: Private
Development stage: Other

Overview

MindBio Therapeutics has completed Phase 1 clinical trials with positive topline data for its lead candidate MB22001 and is currently dosing patients in multiple Phase 2B clinical trials targeting Major Depressive Disorder. The company expects these studies to complete by the end of 2025.

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic medicine
Industry: Biotech

Beyond the preview

Go deeper on mindcaps.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mindcaps.

Explore the full profile